BCL-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53

Journal of Biomedical Science

Volumn 12, Issue 6, 2005, Pages 999-1011

  Basma, Hesham ^a   El Refaey, Hesham ^a   Sgagias, Magdalene K ^b   Cowan, Kenneth H ^b   Luo, Xu ^a,b   Cheng, Pi Wan ^a,b  

^a Dick Holland Regenerative Medicine Program   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Bcl 2 antisense; Breast cancer; Caspase 8; Cisplatin; Cytochrome c; Facilitated lipofection gene delivery strategy; Fas; Liposome; p53

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE 8; CISPLATIN; CYTOCHROME C; FAS ANTIGEN; PROTEIN BCL 2; PROTEIN E6; PROTEIN P53; TRANSFERRIN;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL KILLING; CELL STRAIN MCF 7; CELL VIABILITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CASPASE 8; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYTOCHROMES C; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; HUMANS; INHIBITORY CONCENTRATION 50; LIPOSOMES; MODELS, STATISTICAL; NECROSIS; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHATIDYLETHANOLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION; TRANSFERRIN; TUMOR SUPPRESSOR PROTEIN P53;

MINK CELL FOCUS-FORMING VIRUS;

EID: 30544432958     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-005-9025-y     Document Type: Article

References (54)

1. Jemal A., Tiwari R.C., Murray T. et al., Cancer statistics, 2004. CA Cancer J. Clin. 54: 8-29, 2004.
2. Starcevic S.L., Elferink C. and Novak R.F., Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease. J. Natl. Cancer Inst. 93: 776-782, 2001.
3. Weinstein I.B., Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21: 857-64, 2000.
4. Enari M., Hug H. and Nagata S., Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375: 78-81, 1995.
5. Nagata S., Fas-mediated apoptosis. Adv. Exp. Med. Biol. 406: 119-124, 1996.
6. Nagata S., Apoptosis mediated by the Fas system. Prog. Mol. Subcell. Biol. 16: 87-103, 1996.
7. Cleveland J. and Ihle J., Contenders in FasL/TNF death signaling. Cell 81: 479-82, 1995.
8. Chopin V., Toillon R.A., Jouy N. and Le Bourhis X., Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF- 7 human breast cancer cells. Br. J. Pharmacol. 135: 79-86, 2002.
9. Mullauer L., Mosberger I., Grusch M., Rudas M. and Chott A., Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol; 190: 20-30, 2000.
10. Muschen M., Moers C., Warskulat U., Even J., Niederacher D. and Beckmann M.W., CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 99: 69-77, 2000.
11. Ruiz-Ruiz M.C. and Lopez-Rivas A., p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. Cell Death Differ. 6: 271-280, 1999.
12. Miyashita T., Krajewski S., Krajewska M. et al., Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
13. Green D.R. and Reed J.C., Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
14. Bonnotte B., Favre N., Moutet M. et al., Bcl-2 mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J. Immunol. 161: 1433-1438, 1998.
15. Gutierrez-Puente Y., Zapata-Benavides P., Tari A.M. and Lopez-Berestein G., Bcl-2-related antisense therapy. Semin. Oncol. 29: 71-76, 2002.
16. Crooke S., Antisense therapeutics. Biotechnol. Genet. Eng. Rev. 15: 121-157, 1998.
17. Cotter F., Johnson P., Hall P. et al., Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049-3055, 1994.
18. Jansen B., Schlagbauer-Wadl H., Brown B. et al., Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4: 232-234, 1998.
19. Koty P., Zhang H. and Levitt M., Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23: 115-127, 1999.
20. Zangemeister-Witt U., Schenker T., Luedke G. and Stahel R., Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br. J. Cancer 78: 1035-42, 1998.
21. Schlagbauer-Wadl H., Klosner G., Heere-Ress E. et al., Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J. Invest. Dermatol. 114: 725-730, 2000.
22. Waters J.S., Webb A., Cunningham D. et al., Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18: 1812-1823, 2000.
23. Reed J.C., Kitada S., Takayama S. and Miyashita T., Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann. Oncol. 5: 61-65, 1994.
24. Joshee N., Bastola D.R. and Cheng P.W., Transferrin-facilitated lipofection gene delivery strategy: characterization of the transfection complexes and intracellular trafficking. Hum. Gene Ther. 13: 1991-2004, 2002.
25. Yanagihara K., Cheng H. and Cheng P.W., Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells. Cancer Gene Ther. 7: 59-65, 2000.
26. Cheng P.W., Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum. Gene Ther. 7: 275-282, 1996.
27. Seki M., Iwakawa J., Cheng H. and Cheng P.W., p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum. Gene Ther. 13: 761-773, 2002.
28. Xu L., Pirollo K.F., Tang W.H., Rait A. and Chang E.H., Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 10: 2941-52, 1999.
29. Kim R., Tanabe K., Emi M., Uchida Y. and Toge T., Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells. Cancer 103: 2199-2207, 2005.
30. Tanabe K., Kim R., Inoue H., Emi M., Uchida Y. and Toge T., Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int. J. Oncol. 22: 875-81, 2003.
31. Chi K.C., Wallis A.E., Lee C.H. et al., Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res. Treat. 63: 199-212, 2000.
32. Kuwana T., Smith J.J., Muzio M., Dixit V., Newmeyer D.D. and Kornbluth S., Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J. Biol. Chem. 273: 16589-16594, 1998.
33. Deng Y., Ren X., Yang L., Lin Y. and Wu X., A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115: 61-70, 2003.
34. Rehemtulla A., Hamilton C.A., Chinnaiyan A.M. and Dixit V.M., Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem; 272: 25783-25786, 1997.
35. Luo X., Budihardjo I., Zou H., Slaughter C. and Wang X., Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
36. Shimizu S., Eguchi Y., Kamiike W. et al., Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 13: 21-29, 1996.
37. Bae I., Smith M., Sheikh M. et al., An abnormality in the p53 pathway following gamma-irradiation in many wildtype p53 human melanoma lines. Cancer Res. 56: 840-847, 1996.
38. Li G., Bush J.A. and Ho V.C., p53-dependent apoptosis in melanoma cells after treatment with camptothecin. J. Invest. Dermatol. 114: 514-519, 2000.
39. O'Connor P.M., Jackman J., Bae I. et al., Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57: 4285-4300, 1997.
40. Weinstein J.N., Myers T.G., O'Connor P.M. et al., An information- intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997.
41. Sheard M.A., Uldrijan S. and Vojtesek B., Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells. Cancer Res. 63: 7176-7184, 2003.
42. Fan S., Smith M.L., Rivet D.J. 2nd, et al., Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55: 1649-1654, 1995.
43. Janicke R.U., Ng P., Sprengart M.L. and Porter A.G., Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J. Biol. Chem. 273: 15540-15545, 1998.
44. Dole M., Nunez G., Merchant A.K. et al., Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 54: 3253-3259, 1994.
45. Simoes-Wust A.P., Schurpf T., Hall J., Stahel R.A. and Zangemeister-Wittke U., Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res. Treat. 76: 157-166, 2002.
46. Lopes D. and Mayer L.D., Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol. 49: 57-68, 2002.
47. Leung S., Miyake H., Zellweger T., Tolcher A. and Gleave M.E., Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer 91: 846-850, 2001.
48. Klasa R.J., Bally M.B., Ng R., Goldie J.H., Gascoyne R.D. and Wong F.M., Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res. 6: 2492-2500, 2000.
49. Schaaf A., Sagi S., Langbein S., Trojan L., Alken P. and Michel M.S., Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol. Oncol. 22: 188-192, 2004.
50. Hopkins-Donaldson S., Cathomas R., Simoes-Wust A.P. et al., Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int. J. Cancer 106: 160-166, 2003.
51. Wacheck V., Losert D., Gunsberg P. et al., Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 13: 393-400, 2003.
52. Kim R., Emi M., Tanabe K. and Toge T., Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma. Cancer 101: 2177-2186, 2004.
53. Wacheck V., Heere-Ress E., Halaschek-Wiener J. et al., Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J. Mol. Med. 79: 587-593, 2001.
54. Zupi G., Scarsella M., Semple S.C., Mottolese M., Natali P.G. and Leonetti C., Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin. Cancer Res. 11: 1990-1998, 2005.